More interestingly, for testicular cancer, a tumor that is highly sensitive to cisplatin, almost all of the few refractory patients have been found to harbor wild-type p53, which is not consistent with the commonly accepted view that tumors with p53 mutations are more therapy-resistant [95]. This evidence concerns the gene TP53 and testicular cancer.